Effect of Various Doses of Silymarin on the Oxidative Stress Induced by Busulfan Administration in the Different Organs of Rats/Sicanlarin Farkli Organlarinda Busulfan Aliminin Neden Oldugu Oksidatif Stress Uzerine Cesitli Dozlarda Silimarin Etkisi.
Free radicals and other reactive oxygen species (ROS) are constantly formed in the human body and are also removed by endogenous antioxidant defense mechanism that acts by scavenging free radicals, decomposing peroxides and / or binding with pro-oxidant metal ion. Free radicals interact with other molecules within cells (1). This can cause oxidative damage to proteins, membranes and genes. Oxidative stress, defined as a disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses, is discussed in relation to its possible role in the production of tissue damage (1-2). Many factors such as lifestyle, drugs, toxicants, nutritional imbalances, and infections lead to oxidative stress. Busulfan is an alkylating chemotherapeutic agent used to treat chronic leukemia, ovarian cancer, lymphoma and myeloproliferative disorders and is also used before bone marrow transplantation in cancer patients (3). Busulfan has side effects on various organs including the liver, skin, bladder, nervous system and gonadal function, and is potentially carcinogenic and mutagenic. There is some evidence that Busulfan has the potential to induce free radical damage to lipid peroxidation (4). Interest in natural sources of antioxidant molecules for use in the food, beverage and cosmetic industries has resulted in a large body of research in recent years. It is well known that natural antioxidants extracted from herbs and spices have high antioxidant activity and are used in many food applications. Of these substances, the phenolic compounds, which are widely distributed, have the ability to scavenge free radicals by single-electron transfer (5-6). Silymarin is a known standardized extract obtained from seeds of silybum marianum and is also called "milk thistle". Silybum marianum is one of the family Asteraceae (7-8). Silymarin consists of a large number of flavolignans, including taxifolin, silychristin, silydianin, silybin A, silybin B (silybin or silybinin is the most active component), isosilybin A and isosilybin B (9-11). It has been reported as having multiple pharmacological activities including antioxidant, hepatoprotectant and anti-inflammatory agent, antibacterial, antiallergic, antimutagenic, antiviral, antineoplastic, antithrombotic agents, and vasodilatory actions (12). Asghar and Masood (8) suggested that Silymarin may be used in preventing free radical-related diseases as a dietary natural antioxidant supplement (8). It is suggested that many of these properties may be related to the antioxidant and free radical scavenging activity of Silymarin. Silymarin has been said to be at least ten times more potent in antioxidant activity than vitamin E (13). It increases glutathione in the liver by more than 35% in healthy subjects and by more than 50% in rats (14). Glutathione is responsible for detoxifying a wide range of hormones, drugs, and chemicals. High levels of glutathione in the liver increase its capacity for detoxification. Silymarin also increases the level of the important antioxidant enzyme superoxide dismutase in cell cultures (15). Silymarin inhibits the synthesis of leukotrienes, mediators of inflammation (16).
Based on this evidence, the aim of this study is to determine whether Busulfan has an oxidative effect after administration and whether different doses of Silymarin can protect different organs from Busulfan oxidative-induced damage.
Animals and experimental design
This study was performed at the Animal House of School of Veterinary Medicine, Shiraz University, Iran. Forty-eight Wistar male rats (250 [+ or -] 20) were housed in wire cages at 22 [+ or -] 1[degrees]C under a 12 h light-dark cycle with 30% humidity and fed a standard diet and water.
All chemicals and drugs (Busulfan and Silymarin) were purchased from Sigma-Aldrich and used without further purification. The rats were randomly divided into six equal groups of eight rats in each group as follows: Group 1 (C1) - control group (received nothing). Group 2 (C2) - control Silymarin (Sigma, Aldrich, USA), 175 mg/kg/day Silymarin was given by gavage for 14 days. Group 3 (C3) - anemic control group, received 20 mg/kg/day (i.p.) Busulfan (Sigma, Aldrich, USA) for 14 days. Group 4 (T1) - experimental group 1 received 20 mg/kg/day Busulfan (i.p.) for 14 days and after 2 weeks of 175 mg/kg/day Silymarin was gavage for 14 days. Group 5 (T2) - 2 groups received 20 mg/kg/day dose Busulfan (i.p.) for 14 days and after 2 weeks of 250 mg/kg/day Silymarin was gavage for 14 days. Group 6 (T3) - 3 groups received 20 mg/kg/day dose Busulfan (i.p.) for 14 days and after 2 weeks of 325 mg/kg/day Silymarin was gavage for 14 days.
At the end of the treatment period the rats were anesthetized by using ether then killed; after sacrifice the peritoneal cavity was opened through a lower transverse abdominal incision and their organs were promptly collected. The organs collected were testis, spleen, kidneys, liver, pancreas and heart and were used for determination of organ SOD, GPX activity and MDA concentration. Small pieces of each organ were then transferred to a sterile vessel containing phosphate buffer 0.025 M (pH 7.4) solution. Then the organs were immediately ground to make a tissue homogenate (1 g/4 mL). The homogenates were centrifugated at 750 g for 15 minutes and the supernatant was collected as a tissue extract for biochemical analysis.
This experiment was accomplished under the approval of the State Committee on Animal Ethics, Shiraz University, Shiraz, Iran. The recommendations of European Council Directive (86/609/EC) of November 24, 1986 regarding the standards in the protection of animals used for experimental purposes were also followed.
SOD activity was measured with a commercial kit (RANSOD kit, Randox Com, UK). Tissue homogenates glutathione peroxidase (GPX) enzyme activity was estimated by Ransel spectrophotometric kit (RANSEL, Randox Laboratories Ltd. UK). Tissue homogenates malondialdehyde (MDA) was measured using the colorimetric method described by Placer (17) based on the reaction of thiobarbituric acid (TBA) with MDA, one of the aldehyde products of lipid peroxidation. The absorbance of the MDA-TBA adduct thus produced was measured spectrophotometrically at 532 nm. The results were expressed in terms of the mmol of malondialdehyde (MDA) / mg of tissue homogenates total protein.
Data were analyzed by one-way analysis of variance followed by Duncan's multiple range test using SPSS software package, version 18. The values are Mean [+ or -] SEM for eight rats in each group. P value < 0.05 was considered as significant and included in the study.
The tissue SOD activity manifestations
The lowest activity of SOD of liver was seen in C3 group as compared to the C1 group (p<0.05). The activity of SOD in C2 group, T1, T2 and T3 group showed significant increase compared to the C3 group (p<0.05). The lowest activity of SOD of spleen was seen in C3 group compared to the C1 group (p<0.05). The activity of SOD in C2 groups has increased significantly in comparison to C3 group (p<0.05). The activity of SOD of pancreas in C3 group showed a significant decrease compared to other groups (p <0.05).The lowest activity of SOD of testis was seen in C3 group as compared to the other groups (p<0.05). The activity of SOD in C2 group and T1, T2 and T3 group increased compared to the C3 group but not to C1 group. The lowest activity of SOD of testis was seen in C3 group compared to the other groups (p<0.05). The other groups (C1, C2, T1, T2 and T3) showed a significant increase compared to C3 group (p <0.05). The activity of SOD of kidney in C3 group showed a significant decrease--to other groups (p <0.05) (Table 1).
The tissue GPX activity manifestations
The activity of liver GPX in C1 and C2 group increased remarkably compared to other groups (p <0.05). The highest activity of spleen GPX was seen in the C1 in comparison to other groups (p <0.05). The lowest activity of GPX of pancreas was seen in C3 group compared to the other groups and C2 group has increased significantly compared to C1, T1, T2 and T3 groups (p <0.05). The testis GPX activity of C3 group showed significant decrease compared to group which received different doses of Silymarin (p <0.05). The GPX activity of heart in C2 group compared to C3 group and C1 group had a significant increase (p <0.05). The highest kidney activity of GPX belonged to C1 and C2 groups compared to the other groups and C3 group showed a significant decrease compared to C1 and C2 groups (p <0.05) (Table 2).
The tissue MDA level manifestation
The results indicated that the highest MDA level of liver, spleen, pancreas, testis, heart and kidney was seen in C3 group compared to other groups (p <0.05) (Table 3).
Tissue SOD and GPX alteration
Tissue SOD results indicate that SOD activity of different organs in C3 (liver, spleen, pancreas, testis, heart and kidney) is significantly decreased due to Busulfan administration and this event shows that Busulfan could induce oxidative stress and reduction of SOD as the first antioxidant defense for neutralization of ROS produced by Busulfan. It was evident from data that SOD activity in C2 group was remarkably increased as compared to rats treated with only Busulfan (C3). Also, different doses of Silymarin could increase SOD activity that has been decreased by Busulfan. But there was no dose dependent manner. The results indicate the protective antioxidant effect of Silymarin on oxidative stress induced by Busulfan. Tissue GPX activity in the control group treated with Busulfan was lower than control and Silymarin control groups. This observation shows oxidative potential of Busulfan. Except for liver and spleen, in other organs administration of different doses of Silymarin in combination with Busulfan could increase the activity of GPX. This case may be due to different content of SOD in organs other than GPX. Another reason is probably that tissues responses to treatment are different from each other. Treatment with only Silymarin could increase GPX activity and the antioxidant effect of Silymarin is also indicated. Some experimental studies confirm our study. Das et al. (13) examined the efficacy of Silymarin on the immunomodulatory activity and vascular function in mice with liver abnormalities induced by chronic ethanol consumption. They found that chronic ethanol consumption increased MDA and glutathione S transferase (GST) and decreased the activity of catalase and SOD and GPX and Silymarin treatment reduced MDA and GST and elevated SOD, GPX and catalase. So they suggested that Silymarin can effectively ameliorate ethanol induced oxidative challenges (13). Similarly in Tzeng et al.'s (18) study, it was indicated that Silymarin (200 mg/kg, 3 times a day) could decrease the activity of plasma AST and ALT and increase the activity of liver SOD and GPX in comparison to mice that received [CCl.sub.4] intraperitoneally. [CCl.sub.4] could induced hepatic fibrosis and increased the plasma AST and ALT level and decreased the liver SOD and GPX (23). Our findings are in agreement with Sajedianfard et al. (19). Their study showed that in diabetic rats, high therapeutic doses of Silymarin had a major effect on serum antioxidant factors. They revealed that Silymarin plays a role by increasing antioxidant enzymes level (19, 20). Some chemotherapeutic agents induce oxidative stress as a mechanism for killing cancer cells. However, certain chemotherapeutic agents induce oxidative stress in nontargeted tissues and thereby lead to "normal tissue injury." Although chemotherapy improves the survival rates of cancer patients, oxidative stress- mediated impairment of normal tissues is a significant side effect and decreases the quality of life of patients (21). So far there have been no studies about the effect of Busulfan on the body fluid or tissue SOD and GPX activity.
Tissue MDA alteration
The present study shows that the MDA level of different organs (liver, spleen, pancreas, testis, heart and kidney) in the Busulfan control group was significantly increased as compared to other groups. In the present study the elevated tissue MDA level as a marker of oxidative stress and decreased antioxidant enzymes activity simultaneously in rats treated only with Busulfan indicated the pro-oxidant role of Busulfan in producing ROS and lipid peroxidation (22). This point is in agreement with the findings of Hosseini Ahar et al. (23). Their study on body and testicular weight and serum malondialdehyde (MDA) enzyme in rat was performed following the use of Busulfan. They concluded that the use of Busulfan can reduce body and testicular weight, and increase serum MDA and there could be side effects in reproduction process (23). It has been shown that combined treatment of Busulfan, Melatonin and liver growth factor reduces the Busulfan side effects (24), such as the study conducted by Ray et al. (22). They explored the protective effects of water extract of Spirulina platensis (blue green algae) on Busulfan-induced lipid peroxidation using goat liver as the lipid source and found lipid peroxidation induction capacity of Busulfan and the antiperoxidative potential of water extract of Spirulina platensis (blue green algae) on Busulfan-induced lipid peroxidation (22). In another investigation Ray et al. revealed that ascorbic acid could suppress the drug induced lipid peroxidation such as Busulfan to a significant extent (4). Some studies have shown that Silymarin's protective effect was also reflected on preserving the integrity of the plasma membrane and it seems Silymarin can affect [Ca.sup.2+] modulation as an essential role in hepatoprotection produced by Silymarin (25, 26).
In conclusion, the present data demonstrated that Busulfan as an anticancer drug along with its therapeutic effects has side effects like other drugs and some of these effects could be due to its pro-oxidative effect in inducing oxidative stress. On the other hand, Silymarin as an ancient herbal drug could be a useful antioxidant agent to protect against oxidative damages induced by Busulfan and could be considered as an alternative treatment for protecting the side effects of Busulfan.
The researchers would like to thank the Research Council of Shiraz University and School of Veterinary Medicine, Shiraz University for financial and technical support of this study.
(1.) Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Fludarabine and pharmacokinetic-targeted Busulfan before allografting for adults with acute lymphoid leukemia, Biol Blood Marrow Transplant 17, 1505-11, 2011.
(2.) Betteridge DJ, What is oxidative stress? Metabolism 49, 3-8, 2000.
(3.) Anjamrooz SH, Movahedin M, Mowla SJ, Bairanvand SP, Assessment of morphological and functional changes in the mouse testis and epididymal sperms following Busulfan treatment, Iran Biomed J 11, 15-22, 2007.
(4.) Ray S, Exploring protective role of ascorbic acid on Busulfan-induced lipid peroxidation, Int J Biol Chem Sci 2, 702-708, 2011.
(5.) Hirano R, Sasamoto W, Matsumoto A, Itakura H, Igarashi O , Kondo K, Antioxidant ability of various flavonoids against DPPH radicals and LDL oxidation, J Nutr Sci Vitaminol 47, 357-362, 2001.
(6.) Ibrahim M, Hassan W, Deobald AM, Braga AL, Rocha JB, An organoselenium drug with antioxidant activity and free radical scavenging capacity in vitro, Biol Trace Elem Res 149, 399-404, 2012.
(7.) Anthony K, Saleh MA, Chemical profiling and antioxidant activity of commercial milk histle food supplements, J Chem Pharm Res 4(10), 4440-4450, 2012.
(8.) Asghar Z, Masood Z, Evaluation of antioxidant properties of Silymarin and its potential to inhibit peroxyl radicals in vitro, Pak J Pharm Sci 21, 249-254, 2008.
(9.) Lee DY, Liu Y, Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle), J Nat Prod 66, 1171-1174, 2003.
(10.) Khan SA, Ahmad B, Alam T, Synthesis and antihepatotoxic activity of some new chalcones containing 1, 4 - dioxane ring system, Pak J Pharm Sci 19, 290-294, 2006.
(11.) Anthony K, Subramanya G, Uprichard S, Hammouda F, Saleh M, Antioxidant and anti-hepatitis C viral activities of commercial milk thistle food supplements, Antioxidants 2, 23-36, 2013.
(12.) Abascal KYE, The many faces of Silybum marianum (milk thistle), Alter Complement Ther 9, 251-256, 2003.
(13.) Das SK, Mukherjee S, Biochemical and immunological basis of Silymarin effect, a milk thistle (Silybum marianum) against ethanol-induced oxidative damage, Toxicol Mech Methods 22, 409-413, 2012.
(14.) Valenzuela A, Aspillaga M, Vial S, Guerra R, Selectivity of Silymarin on the increase of the glutathione content in different tissues of the rat, Planta Med 55, 420-422, 1989.
(15.) Soto C, Recoba R, Barron H, Alvarez C, Favari L, Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas, Comp Biochem Physiol C Toxicol Pharmacol 136, 205-212, 2003.
(16.) Nassuato G, Iemmolo RM, Strazzabosco M, Lirussi F, Deana R, Francesconi MA, Effect of silibinin on biliary lipidcomposition: experimental and clinical study, J Hepatol 12, 290-295, 1991.
(17.) Placer ZA, Cushman LL, Johnson BC, Estimation of product of lipid peroxidation (malondialdehyde) in biochemical systems, Anal Biochem 16, 395-364, 1966.
(18.) Tzeng JI, Chen MF, Chung HH, Cheng JT, Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride, Phytother Res 2013, 1023-1028, 2013.
(19.) Sajedianfard J, Nazifi S, Shamsaei HA, The effects of oral administration of different doses of hydroalcoholic extract of Silymarin on status of serum trace elements, Am J Anim Vet Sci 9, 170-176, 2014.
(20.) Alimoradian A, Sajedianfard J, Baha-Aldini Beigy F, Panjehshahin MR, Owji AA,
Relationship of dopamine of the nucleus accumbens with intra-infralimbic apomorphine microinjection, Iran J Basic Med Sci 16, 743-750, 2013.
(21.) Tangpong J, Cole MP, Sultana R, Estus S, Vore M, St Clair W, Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain, J Neurochem 100, 191-201, 2007.
(22.) Ray S, Evaluation of antiperoxidative potential of ascorbic acid on Busulfan-induced lipid peroxidation using 4-hydroxy-2-nonenal and nitric oxide as model markers, Int J Life Sci Pharma Res 1(1), L21-L27, 2011.
(23.) Hosseini Ahar NKA, Akbari G, Chalfari Novin M, The effect of Busulfan on body weight , testis weight and MDA enzymes in male rats, Int J Fertil Womens Med 2, 316-319, 2014.
(24.) Zahedi AKA, Ahmadi-Ashtiani H, Rastegar H, Rezazadeh S, Zingiber officinale protective effects on gentamicin's toxicity on sperm in rats, J Med Plants 9, 93-98, 2010.
(25.) Farghali H, Kamenikova L, Hynie S, Kmonickova E, Silymarin effects on intracellular calcuim and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury, Pharmacol Res 41, 231-237, 2000.
(26.) Sierra-Santoyo A, Lopez ML, Hernandez A, Mendoza-Figueroa T, Urea production in long-term cultures of adult rat hepatocytes, In Vitro Toxicol 8, 293-299, 2013.
Javad SAJEDIANFARD (1*), Saeed NAZIFI (2), Arezoo IZADI (1), Marjan CHAHARDAHCHERIK (1), Masoumeh HONARMAND (2)
(1) Shiraz University, School of Veterinary Medicine, Department of Basic Science, Shiraz, IRAN, (2) Shiraz University, School of Veterinary Medicine, Department of Clinical Studies, Shiraz, IRAN
Correspondence: E-mail: email@example.com; Tel: +98-711-2286940
Table 1. Effect of Busulfan and Silymarin administration on changes in SOD activity profile (Mean [+ or -] SEM). Dissimilar letters in each column indicate significant differences between the different groups (p<0.05). Tissues/Gruops Liver Spleen (T1) 41.54 [+ or -]7.71 (b) 36.97[+ or -]1.85 (ab) (T2) 43.86 [+ or -]7.51 (b) 47.00[+ or -]3.72 (bc) (T3) 42.00[+ or -]1.95 (b) 58.09[+ or -]2.45 (cd) (C3) 18.67[+ or -]1.94 (a) 31.32[+ or -]3.34 (a) (C2) 50.92[+ or -]7.66 (b) 63.91[+ or -]5.95 (d) (C1) 40.86[+ or -]3.82 (b) 55.40[+ or -]4.20 (cd) Tissues/Gruops Pancreas Testis (T1) 35.17[+ or -]4.96 (b) 39.50[+ or -]4.19 (b) (T2) 39.05[+ or -]3.12 (bc) 47.82[+ or -]3.28 (b) (T3) 41.87[+ or -]3.60 (bc) 48.24[+ or -]3.07 (b) (C3) 18.23[+ or -]3.30 (a) 23.99[+ or -]3.33 (a) (C2) 51.70[+ or -]6.49 (c) 47.00[+ or -]3.79 (b) (C1) 49.07[+ or -]5.95 (bc) 43.08[+ or -]5.04 (b) Tissues/Gruops Heart Kidney (T1) 60.58[+ or -]3.76 (b) 46.55[+ or -]6.48 (b) (T2) 57.70[+ or -]9.16 (b) 52.55[+ or -]6.98 (b) (T3) 57.37[+ or -]3.36 (b) 58.05[+ or -]3.23 (b) (C3) 23.16[+ or -]2.24 (a) 13.42[+ or -]1.39 (a) (C2) 66.88[+ or -]4.61 (b) 58.58[+ or -]5.79 (b) (C1) 56.88[+ or -]4.44 (b) 48.58[+ or -]5.38 (b) Table 2. Effect of Busulfan and Silymarin administration on changes in GPX activity profile (Mean[+ or -]SEM). Dissimilar letters in each column indicate significant differences between the different groups (p<0.05). Tissues /Groups Liver Spleen (T1) 6.97[+ or -]0.59 (a) 11.08[+ or -]0.98 (a) (T2) 6.72[+ or -]0.55 (a) 12.86[+ or -]1.00 (ab) (T3) 7.03[+ or -]0.62 (a) 13.07[+ or -]3.35 (ab) (C3) 8.91[+ or -]1.05 (a) 14.23[+ or -]0.82 (ab) (C2) 15.39[+ or -]1.08 (b) 18.90[+ or -]0.94 (b) (C1) 15.43[+ or -]0.89 (b) 27.80[+ or -]4.61 (c) Tissues /Groups Pancreas Testis (T1) 6.67[+ or -]0.61 (b) 6.28[+ or -]0.77 (bc) (T2) 6.58[+ or -]0.50 (b) 6.88[+ or -]0.63 (c) (T3) 7.36[+ or -]0.27 (b) 6.89[+ or -]0.60 (c) (C3) 3.01[+ or -]0.17 (a) 4.13[+ or -]0.21 (a) (C2) 12.91[+ or -]0.92 (d) 5.07[+ or -]0.27 (ab) (C1) 10.52[+ or -]0.68 (c) 5.36[+ or -]0.34 (abc) Tissues /Groups Heart Kidney (T1) 8.76[+ or -]0.78 (ab) 10.53[+ or -]0.54 (ab) (T2) 8.85[+ or -]1.29 (ab) 11.92[+ or -]0.80 (b) (T3) 13.27[+ or -]2.27 (bc) 10.81[+ or -]0.75 (ab) (C3) 4.72[+ or -]0.54 (a) 8.57[+ or -]0.61 (a) (C2) 17.45[+ or -]3.98 (c) 15.80[+ or -]1.17 (c) (C1) 10.12[+ or -]0.68 (ab) 15.58[+ or -]0.89 (c) Table 3. Effect of Busulfan and Silymarin administration on changes in MDA profile (Mean[+ or -]SEM). Dissimilar letters in each column indicate significant differences between the different groups (p<0.05). Tissues/Groups Liver Spleen (T1) 5.70[+ or -]0.03 (a) 5.71[+ or -]0.02 (a) (T2) 5.70[+ or -]0.02 (a) 5.71[+ or -]0.02 (a) (T3) 5.81[+ or -]0.03 (a) 5.83[+ or -]0.02 (a) (C3) 9.33[+ or -]0.22 (b) 9.47[+ or -]0.22 (b) (C2) 5.79[+ or -]0.03 (a) 5.81[+ or -]0.02 (a) (C1) 5.98[+ or -]0.03 (a) 5.99[+ or -]0.04 (a) Tissues/Groups Pancreas Testis (T1) 5.72[+ or -]0.02 (a) 5.75[+ or -]0.03 (a) (T2) 5.73[+ or -]0.03 (a) 5.70[+ or -]0.03 (a) (T3) 5.82[+ or -]0.03 (ab) 5.84[+ or -]0.04 (a) (C3) 9.39[+ or -]0.23 (c) 9.40[+ or -]0.23 (b) (C2) 5.80[+ or -]0.03 (ab) 5.82[+ or -]0.04 (a) (C1) 6.03[+ or -]0.02 (b) 6.00[+ or -]0.04 (a) Tissues/Groups Heart Kidney (T1) 5.71[+ or -]0.02 (a) 5.71[+ or -]0.02 (a) (T2) 5.70[+ or -]0.02 (a) 5.69[+ or -]0.03 (a) (T3) 5.82[+ or -]0.03 (ab) 5.83[+ or -]0.03 (ab) (C3) 9.35[+ or -]0.21 (c) 9.41[+ or -]0.22 (c) (C2) 5.79[+ or -]0.03 (ab) 5.80[+ or -]0.03 (ab) (C1) 6.01[+ or -]0.03 (b) 6.00[+ or -]0.03 (b)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original article|
|Author:||Sajedianfard, Javad; Nazifi, Saeed; Izadi, Arezoo; Chahardahcherik, Marjan; Honarmand, Masoumeh|
|Publication:||Turkish Journal of Pharmaceutical Sciences|
|Date:||Aug 1, 2016|
|Previous Article:||Assessment of Cytotoxic Properties of Sinapic Acid In Vitro/Sinapik Asidin Sitotoksik Ozelliklerinin In Vitro Incelenmesi.|
|Next Article:||E-Pharmacophore Mapping Combined with Virtual Screening and Molecular Docking to Identify Potent and Selective Inhibitors of P90 Ribosomal S6 Kinase...|